keyword
MENU ▼
Read by QxMD icon Read
search

HIV-related lymphoma

keyword
https://www.readbyqxmd.com/read/27905485/b-and-t-lymphocyte-number-and-function-in-hiv-hiv-lymphoma-patients-treated-with-high-dose-chemotherapy-and-autologous-bone-marrow-transplantation
#1
Diego Bertoli, Alessandro Re, Marco Chiarini, Alessandra Sottini, Federico Serana, Viviana Giustini, Aldo M Roccaro, Chiara Cattaneo, Luigi Caimi, Giuseppe Rossi, Luisa Imberti
Combination of anti-retroviral therapy, high-dose chemotherapy (HCT) and autologous stem cell transplantation (ASCT) has led to an improved survival of HIV(+) non-Hodgkin lymphoma (NHL) patients. We compared T- and B-cell subset recovery and related capability to respond to in-vitro stimulation, as well as T-cell repertoire modifications of HIV(+) and HIV(-) NHL patients undergoing HCT and ASCT as first-line consolidation or salvage treatment, using sequential blood samples obtained before and at 3, 6, 12 and 24 months after ASCT...
December 1, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27888664/ebv-associated-but-hhv8-unrelated-double-hit-effusion-based-lymphoma
#2
Bo-Jung Chen, David Yen-Ting Chen, Chun-Chi Kuo, Shih-Sung Chuang
Effusion-based lymphoma is a rare and unique type of large B-cell lymphoma presenting in effusion without a mass lesion. It shares many clinicopathological features with primary effusion lymphoma (PEL), but is distinct from PEL by the absence of HHV8 association. Double hit lymphoma (DHL) is an aggressive B-cell lymphoma, defined by concurrent rearrangement of MYC and BCL2 or BCL6. DHL often presents as lymphadenopathy or an extranodal mass, but rarely occurs in effusion. Here we report a 61-year-old male with alcoholic cirrhosis presenting as massive ascites and left pleural effusion...
November 26, 2016: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/27882054/risk-of-cancer-among-commercially-insured-hiv-infected-adults-on-antiretroviral-therapy
#3
Jeannette Y Lee, Ishwori Dhakal, Corey Casper, Ariela Noy, Joel M Palefsky, Missak Haigentz, Susan E Krown, Richard F Ambinder, Ronald T Mitsuyasu
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database...
2016: Journal of Cancer Epidemiology
https://www.readbyqxmd.com/read/27870005/hiv-protease-inhibitors-for-the-treatment-of-cancer-repositioning-hiv-protease-inhibitors-while-developing-more-potent-no-hybridized-derivatives
#4
REVIEW
Danijela Maksimovic-Ivanic, Paolo Fagone, James McCubrey, Klaus Bendtzen, Sanja Mijatovic, Ferdinando Nicoletti
The possible use of HIV protease inhibitors (HIV-PI) as new therapeutic option for the treatment of cancer primarily originated from their success in treating HIV-related Kaposi's sarcoma (KS). While these findings were initially attributed to immune reconstitution and better control of oncogenic viral infections, the number of reports on solid tumors, KS, lymphoma, fibrosarcoma, multiple myeloma, and prostate cancer suggest other mechanisms for the anti-neoplastic activity of PIs. However, a major drawback for the possible adoption of HIV-PIs in the therapy of cancer relies on their relatively weak anticancer potency, and important side effects...
November 21, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27859456/clinical-characteristics-and-survival-outcome-of-primary-effusion-lymphoma-a-review-of-105-patients
#5
Mohamed Abd El-Fattah
Primary effusion lymphoma (PEL) is a rare and an aggressive B-cell non-Hodgkin lymphoma with a distinctive clinicobiological features. As a result of the rarity of this malignancy, the overwhelming majority of data come from a case reports or series. Our study aimed to evaluate the clinical features and the survival outcomes of 105 patients with PEL who diagnosed between 2001 and 2012 from the Surveillance Epidemiology and End Results database 18 of the US National Cancer Institute. The Kaplan-Meier curves were constructed and the multivariate Cox model was built to identify survival prognostic factors...
November 18, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27833967/diagnosing-hiv-associated-cerebral-diseases-the-importance-of-neuropathology-in-understanding-hiv
#6
Ioan Alexandru Diaconu, LaurenŢiu MihăiŢă Stratan, Luciana Nichita, Victoria Aramă, Valentina Ruxandra Moroti Constantinescu, Alexandra Ioana Diaconu, Daniela Adriana Ion
The study aims to compare two aspects concerning the diagnosis of acquired immune deficiency syndrome (AIDS)-associated central nervous system (CNS) pathology (neuroAIDS): clinical diagnoses issued ante mortem with pathology results issued post mortem. The group of 39 human immunodeficiency virus (HIV)-positive patients was created over 23 years and is limited by marked heterogeneity. The enrolled cases were treated at the "Prof. Dr. Matei Bals" National Institute for Infectious Diseases, Bucharest, Romania, deceased due to AIDS-related complications and underwent brain necropsies performed in the Pathology Laboratory at the "Colentina" Clinical Hospital, Bucharest...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27822455/burden-of-cancers-attributable-to-infectious-agents-in-nigeria-2012-2014
#7
Michael Odutola, Elima E Jedy-Agba, Eileen O Dareng, Emmanuel Aja Oga, Festus Igbinoba, Theresa Otu, Emmanuel Ezeome, Ramatu Hassan, Clement A Adebamowo
INTRODUCTION: Infections by certain viruses, bacteria, and parasites have been identified as risk factors for some cancers. In Nigeria, like many other developing countries, infections remain a leading cause of morbidity and mortality. While there are data on the incidence of different cancers in Nigeria, there has been no study of cancers attributable to infections. This study was carried out to determine the burden of cancers attributable to infections using data from two population-based cancer registries (PBCRs) in Nigeria...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27819680/syndecan-1-increases-b-lymphoid-cell-extravasation-in-response-to-hiv-1-tat-via-%C3%AE-v%C3%AE-3-pp60src-pp125fak-pathway
#8
C Urbinati, E Grillo, P Chiodelli, C Tobia, F Caccuri, S Fiorentini, G David, M Rusnati
Syndecan-1 is a heparan sulfate proteoglycan (HSPG) commonly upregulated in AIDS-related B lymphoid malignancies. Tat is the main HIV-1 transactivating factor that has a major role in the pathogenesis of AIDS-related lymphomas (ARL) by engaging heparan sulfate proteoglycans (HSPGs), chemokine receptors and integrins at the lymphoid cell (LC) surface. Here B-lymphoid Namalwa cell clones that do not express or overexpress syndecan-1 (EV-Ncs and SYN-Ncs, respectively) were compared for their responsiveness with Tat: in the absence of syndecan-1, Tat induces a limited EV-Nc migration via C-X-C motif chemokine receptor 4 (CXCR4), G-proteins and Rac...
November 7, 2016: Oncogene
https://www.readbyqxmd.com/read/27755153/combination-antiretroviral-therapy-and-cancer-risk
#9
Álvaro H Borges
PURPOSE OF REVIEW: To review the newest research about the effects of combination antiretroviral therapy (cART) on cancer risk. RECENT FINDINGS: HIV+ persons are at increased risk of cancer. As this risk is higher for malignancies driven by viral and bacterial coinfections, classifying malignancies into infection-related and infection-unrelated has been an emerging trend. Cohorts have detected major reductions in the incidence of Kaposi sarcoma and non-Hodgkin lymphoma (NHL) following cART initiation among immunosuppressed HIV+ persons...
January 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/27755151/epstein-barr-virus-associated-lymphomas-in-people-with-hiv
#10
Antonino Carbone, Chiara C Volpi, Ambra V Gualeni, Annunziata Gloghini
PURPOSE OF REVIEW: The present review summarizes the association of the different histotypes of Epstein-Barr virus (EBV)-associated lymphomas with known genetic lesions and/or oncogenic viruses. A more comprehensive understanding of the complex interplay existing between genetic abnormalities of tumor cells and the viral contribution to the development of EBV-associated lymphomas is pivotal for the development of more effective treatments. RECENT FINDINGS: Recent evidence indicates that HIV may contribute to lymphomagenesis by acting directly on B lymphocytes as a critical microenvironmental factor...
January 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/27746042/rituximab-in-lymphoma-and-chronic-lymphocytic-leukaemia-a-practice-guideline
#11
A Prica, F Baldassarre, L K Hicks, K Imrie, T Kouroukis, M Cheung
Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aimed to systematically review and update the literature on rituximab in lymphoma and CLL, and provide evidence-based consensus guidelines for its rational use. Validated methodology from the Cancer Care Ontario Program in Evidence-based Care was used. A comprehensive literature search was completed by a methodologist from the Hematology Disease Site Group of Cancer Care Ontario...
October 13, 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/27738277/a-rare-presentation-of-plasmablastic-lymphoma-as-cutaneous-nodules-in-an-immunocompromised-patient
#12
Selvin Sundar Raj Mani, Thomas Kodiatte, Manjeera Jagannati
Plasmablastic lymphoma is a rare entity accounting for around 2.7% of all AIDS-related lymphomas. The oral cavity and gastrointestinal tract are the most common sites involved. We report a case of a 34-year-old HIV-positive woman with a rare presentation of cutaneous nodules all over the body. Due to overwhelming tumour burden, she developed tumour lysis syndrome during her hospital stay and succumbed to the illness.
October 13, 2016: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/27735156/primary-maxillary-sinus-plasmablastic-lymphoma-in-hiv-aids
#13
Anita Basavaraj, Manasi Kadam, D B Kadam
Classically, the HIV/AIDS-related lymphomas are of the B cell type and involve the central nervous system and the abdominal cavity. Primary maxillary sinus lymphoma is rare. Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkinvs lymphoma, and is extremely rare. Here we present a case of plasmablastic lymphoma with primary site being maxillary sinus, a rare location.
May 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27701053/microrna-related-polymorphisms-and-non-hodgkin-lymphoma-susceptibility-in-the-multicenter-aids-cohort-study
#14
Erin C Peckham-Gregory, Dharma R Thapa, Jeremy Martinson, Priya Duggal, Sudhir Penugonda, Jay H Bream, Po-Yin Chang, Sugandha Dandekar, Shen-Chih Chang, Roger Detels, Otoniel Martínez-Maza, Zuo-Feng Zhang, Shehnaz K Hussain
BACKGROUND: MicroRNAs, small non-coding RNAs involved in gene regulation, are implicated in lymphomagenesis. We evaluated whether genetic variations in microRNA coding regions, binding sites, or biogenesis genes (collectively referred to as miRNA-SNPs) were associated with risk of AIDS-associated non-Hodgkin lymphoma (AIDS-NHL), and serum levels of four lymphoma-related microRNAs. METHODS: Twenty-five miRNA-SNPs were genotyped in 180 AIDS-NHL cases and 529 HIV-infected matched controls from the Multicenter AIDS Cohort Study (MACS), and real-time polymerase chain reaction was used to quantify serum microRNA levels...
December 2016: Cancer Epidemiology
https://www.readbyqxmd.com/read/27695577/malignancies-trends-in-a-hispanic-cohort-of-hiv-persons-in-puerto-rico-before-and-after-cart
#15
Angel M Mayor, Eduardo J Santiago-Rodriguez, Eddy Rios-Olivares, Guillermo Tortolero-Luna, Robert F Hunter-Mellado
BACKGROUND: The study describes the cancer trends in a Puerto Rican Hispanic HIV/AIDS cohort for three different time periods as defined by the availability of combination antiretroviral therapy (cART) in the Island: pre (1992-1995), early (1996-2002, and recent (2003-2009). METHODS: AIDS and non-AIDS related malignancies risk, standardized incidence rate and one year mortality was evaluated in the cohort before and after cART. RESULTS: Of the 281 malignancies found in 265 persons; 72% were in men, 38% in injecting drug users and 42...
2016: International Journal of Cancer Research
https://www.readbyqxmd.com/read/27662501/kaposi-sarcoma-herpesvirus-associated-cancers-and-related-diseases
#16
Priscila H Goncalves, Joseph Ziegelbauer, Thomas S Uldrick, Robert Yarchoan
PURPOSE OF REVIEW: This review discusses the pathogenesis and recent advances in the management of Kaposi sarcoma herpesvirus (KSHV)-associated diseases. RECENT FINDINGS: KSHV, a gammaherpesvirus, causes several tumors and related diseases, including Kaposi sarcoma, a form of multicentric Castleman disease (KSHV-MCD), and primary effusion lymphoma. These most often develop in patients infected with human immunodeficiency virus (HIV). KSHV inflammatory cytokine syndrome (KICS) is a newly described syndrome with high mortality that has inflammatory symptoms-like MCD but not the pathologic lymph node findings...
January 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/27612583/cancer-related-fatigue-in-patients-with-and-survivors-of-hodgkin-s-lymphoma-a-longitudinal-study-of-the-german-hodgkin-study-group
#17
Stefanie Kreissl, Horst Mueller, Helen Goergen, Axel Mayer, Corinne Brillant, Karolin Behringer, Teresa Veronika Halbsguth, Felicitas Hitz, Martin Soekler, Oluwatoyin Shonukan, Jens Ulrich Rueffer, Hans-Henning Flechtner, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann
BACKGROUND: Patients with Hodgkin's lymphoma might have persistent fatigue even years after treatment. However, knowledge of the development of fatigue persisting long after completion of treatment is limited. Therefore, we did a detailed analysis of fatigue in our first-line clinical trials for early-stage favourable (HD13 trial), early-stage unfavourable (HD14 trial), and advanced-stage (HD15 trial) Hodgkin's lymphoma. Beyond the description of fatigue from diagnosis up to 5 years after treatment, we aimed to assess any effect of patient characteristics, disease characteristics, or treatment characteristics on persistent fatigue...
October 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27576871/long-term-survival-in-aids-related-primary-central-nervous-system-lymphoma
#18
Neel K Gupta, Amber Nolan, Antonio Omuro, Erin G Reid, Chia-Ching Wang, Gabriel Mannis, Michael Jaglal, Julio C Chavez, Paul G Rubinstein, Ann Griffin, Donald I Abrams, Jimmy Hwang, Lawrence D Kaplan, Judith A Luce, Paul Volberding, Patrick A Treseler, James L Rubenstein
BACKGROUND: The optimal therapeutic approach for patients with AIDS-related primary central nervous system lymphoma (AR-PCNSL) remains undefined. While its incidence declined substantially with combination antiretroviral therapy (cART), AR-PCNSL remains a highly aggressive neoplasm for which whole brain radiotherapy (WBRT) is considered a standard first-line intervention. METHODS: To identify therapy-related factors associated with favorable survival, we first retrospectively analyzed outcomes of AR-PCNSL patients treated at San Francisco General Hospital, a public hospital with a long history of dedicated care for patients with HIV and AIDS-related malignancies...
August 30, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27559711/cancer-clinical-trials-in-persons-with-hiv-infection
#19
Richard F Little
PURPOSE OF REVIEW: The era of modern HIV therapeutics is well underway. The cancer and infectious disease epidemiology of HIV disease has markedly altered as populations are availed to the benefits of antiretroviral therapy (ARV). The types of cancers occurring among those with HIV infection has broadened but the case burden in absolute numbers is very low relative to the background population. There are fewer incident cases of the AIDS-defining cancers (aggressive B-cell lymphomas, Kaposi's sarcoma, and cervical cancer)...
January 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/27507879/changes-in-clinical-context-for-kaposi-s-sarcoma-and-non-hodgkin-lymphoma-among-people-with-hiv-infection-in-the-united-states
#20
Elizabeth L Yanik, Chad J Achenbach, Satish Gopal, Anna E Coghill, Stephen R Cole, Joseph J Eron, Richard D Moore, W Christopher Mathews, Daniel R Drozd, Ayad Hamdan, Mary E Ballestas, Eric A Engels
PURPOSE: The biology of HIV-associated cancers may differ depending on immunologic and virologic context during development. Therefore, an understanding of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) relative to antiretroviral therapy (ART), virologic suppression, and CD4 count is important. PATIENTS AND METHODS: KS and NHL diagnoses during 1996 to 2011 were identified among patients with HIV infection in eight clinical cohorts in the United States...
September 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
29904
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"